生物制剂治疗下非感染性葡萄膜炎患者泪液中的潜在预后蛋白生物标志物:迈向个性化医疗的初步研究
本研究为横断面观察性研究,纳入接受阿达木单抗治疗六个月或以上的非感染性葡萄膜炎患者,采用泪液蛋白质组学分析。在无应答者中检出29种差异表达蛋白(14种上调、15种下调),主要与中性粒细胞效应功能增强和氧化还原失衡相关。ROC分析鉴定防御素-1,3、生物素酶和ATP结合盒转运蛋白A1为潜在治疗应答生物标志物。
要点
- 在阿达木单抗无应答者泪液中检出29种差异表达蛋白,主要涉及中性粒细胞效应功能增强和氧化还原失衡。
- 防御素-1,3、生物素酶和ATP结合盒转运蛋白A1被鉴定为潜在治疗应答生物标志物。
- 作者认为靶向白细胞介素6、Janus激酶或补体级联可能是无应答者的潜在替代治疗策略。
核心结论
- 本研究首次在非感染性葡萄膜炎临床队列中鉴定出与中性粒细胞过度活化相关的泪液蛋白,可能驱动阿达木单抗无应答者持续的眼内炎症。
- 研究提供证据表明靶向白细胞介素6、Janus激酶或补体级联可能是这些患者的潜在替代治疗策略。
- 结果表明高通量蛋白质组学有望揭示抗TNF治疗应答不足者持续眼内炎症的潜在病理机制,并体现泪液蛋白质组学作为个性化医疗工具的价值。
研究设计与样本
- 横断面观察性研究,纳入接受阿达木单抗治疗六个月或以上的非感染性葡萄膜炎患者。
- 用微量毛细管收集泪液,采用数据非依赖采集/全理论质谱序列窗口采集法分析蛋白质。
- 根据无应答者与应答者之间表达倍数变化定义差异表达蛋白,并进行蛋白网络和基因本体分析。
- 使用χ2趋势检验和受试者工作特征曲线评估潜在治疗应答生物标志物。
主要发现
- 在无应答者中检出29种差异表达蛋白,其中14种上调、15种下调。
- 这些差异表达蛋白主要与中性粒细胞效应功能增强和氧化还原失衡相关。
- ROC分析鉴定防御素-1,3、生物素酶和ATP结合盒转运蛋白A1为潜在治疗应答生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adalimumab (ADA) is a systemic biological treatment option approved for the treatment of noninfectious uveitis (NIU); however, up to 40% of patients do not respond to the drug, either in a primary or secondary manner. Here, we evaluated the proteomic profile of patients with NIU who fail to ADA to identify proteins implicated in intraocular inflammation, as well as potential biomarkers for treatment response and novel therapeutic targets. METHODS: Cross-sectional observational study of patients with NIU under ADA treatment for six or more months. Tears were collected with microcapillary tubes and protein analyzed by data-independent acquisition/sequential window acquisition of all theoretical mass spectra. Differentially expressed proteins (DEPs) were defined based on the fold change between their expression in nonresponders (NR) and responders (R). Protein network and gene ontology analysis were performed. The χ2 test for trend and receiver operating characteristic (ROC) curves were used to evaluate potential biomarkers of treatment response. RESULTS: Twenty-nine DEPs, 14 upregulated and 15 downregulated, were detected in NR. These proteins were mainly related to enhanced neutrophil effector functions and redox imbalance. ROC analysis identified defensin-1,3 (DEF-1,3), biotinidase, and ATP-binding cassette transporter A1 as potential biomarkers for treatment response. CONCLUSIONS: This is the first study on a clinical cohort of patients with noninfectious uveitis that identifies tear proteins related to neutrophil hyperactivation as drivers of the persistent intraocular inflammation observed in NR to ADA and provides evidence that targeting interleukin 6, Janus kinases, or the complement cascade could be potential alternative therapeutic strategies in these patients. Our results indicate the potential of high-throughput proteomics to provide insights into the underlying pathological mechanisms of persistent intraocular inflammation observed in patients who do not adequately respond to anti-TNF treatment and the value of tear proteomics as a tool for personalized medicine.
引用
- Rodríguez-Martínez L, Rodríguez-Fernández CA, Rodríguez Lemos O, et al. Potential Prognostic Protein Biomarkers in Tears From Noninfectious Uveitis Patients Under Biologic Treatment as a Prelude to Personalized Medicine. Invest Ophthalmol Vis Sci. 2024. PMID: 39540857. doi:10.1167/iovs.65.13.29
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。